For patients with chronic kidney disease, hypertension, and a urinary albumin:creatinine ratio (ACR) of 70 or more, it is recommended to aim for a lower blood pressure target of <130/80 mmHg. This approach can provide advantages such as reducing the risk of cardiovascular complications and slowing the progression of the disease. However, if the patient’s ACR is less than 70 mg/mmol, the blood pressure target can be slightly higher at <140/90 mmHg. For individuals under 80 years old, the recommended target for home blood pressure readings is <135/85 mmHg. Chronic kidney disease (CKD) patients often require more than two drugs to manage hypertension. The first-line treatment is ACE inhibitors, which are especially effective in proteinuric renal disease like diabetic nephropathy. However, these drugs can reduce filtration pressure, leading to a slight decrease in glomerular filtration pressure (GFR) and an increase in creatinine. NICE guidelines state that a decrease in eGFR of up to 25% or a rise in creatinine of up to 30% is acceptable, but any increase should prompt careful monitoring and exclusion of other causes. If the rise is greater than this, it may indicate underlying renovascular disease. Furosemide is a useful Antihypertensive drug for CKD patients, particularly when the GFR falls below 45 ml/min*. It also helps to lower serum potassium levels. However, high doses are usually required, and if the patient is at risk of dehydration (e.g. due to gastroenteritis), the drug should be temporarily stopped. The NKF K/DOQI guidelines suggest a lower cut-off of less than 30 ml/min.

Understanding Nephritis, Angioedema, Chronic Liver Disease, and Hypertensive Emergencies

Nephritis is a condition that causes haematuria, oliguria, proteinuria, facial oedema, and hypertension. It can be caused by various factors, but it is a common complication of SLE, affecting 30-55% of patients. Hypertension is a poor prognostic sign in these patients.

Angioedema, on the other hand, causes facial swelling due to an allergic reaction and is not typically associated with renal abnormalities. Urinary tract infections do not usually cause heavy proteinuria and facial swelling. Chronic liver disease can cause hypoalbuminaemia, but it doesn’t typically cause renal abnormalities on its own.

Hypertensive emergencies include accelerated hypertension and malignant hypertension. Both conditions result in target organ damage due to a recent increase in blood pressure to very high levels (usually ≥180 mm Hg systolic and ≥110 mm Hg diastolic). This damage is usually seen as neurological (e.g., encephalopathy), cardiovascular, or renal damage. In malignant hypertension, papilloedema is present.

Chronic kidney disease (CKD) is a condition where there is an abnormality in kidney function or structure that lasts for more than three months and has implications for health. Diagnosis of CKD requires an eGFR of less than 60 on at least two occasions, separated by a minimum of 90 days. CKD can range from mild to end-stage renal disease, with associated protein and/or blood leakage into the urine. Common causes of CKD include diabetes, hypertension, nephrotoxic drugs, obstructive kidney disease, and multi-system diseases. Early diagnosis and treatment of CKD aim to reduce the risk of cardiovascular disease and progression to end-stage renal disease. Testing for CKD involves measuring creatinine levels in the blood, sending an early morning urine sample for albumin: creatinine ratio (ACR) measurement, and dipping the urine for haematuria. CKD is diagnosed when tests persistently show a reduction in kidney function or the presence of proteinuria (ACR) for at least three months. This requires an eGFR persistently less than 60 mL/min/1.73 m2 and/or ACR persistently greater than 3 mg/mmol. To confirm the diagnosis of CKD, a repeat blood test is necessary at least 90 days after the first one. For instance, a lady needs to provide an early morning urine sample for haematuria dipping and ACR measurement, and another blood test after 90 days to confirm CKD diagnosis.

Chronic kidney disease is often without symptoms and is typically identified through abnormal urea and electrolyte levels. However, some individuals with advanced, undetected disease may experience symptoms. These symptoms may include swelling in the ankles, weight gain, increased urination, fatigue, itching due to uraemia, loss of appetite leading to weight loss, difficulty sleeping, nausea and vomiting, and high blood pressure.

Patients taking warfarin have a comparable incidence of non-visible haematuria to the general population, and thus should be evaluated in the same manner. While most haematuria protocols recommend referring younger patients (under 40 years) to nephrology, this patient’s age warrants referral to urology for a cystoscopy.

Haematuria: Causes and Management

The management of haematuria can be challenging due to the lack of widely followed guidelines. Haematuria is now classified as visible or non-visible, with the latter being found in approximately 2.5% of the population. Transient or spurious non-visible haematuria can be caused by urinary tract infections, menstruation, vigorous exercise, or sexual intercourse. Persistent non-visible haematuria may be caused by cancer, stones, benign prostatic hyperplasia, prostatitis, urethritis, or renal conditions such as IgA nephropathy or thin basement membrane disease. Spurious causes of haematuria include certain foods and drugs.

Screening for haematuria is not recommended, and patients taking aspirin or warfarin should also be investigated. Urine dipstick is the preferred test for detecting haematuria, and persistent non-visible haematuria is defined as blood being present in 2 out of 3 samples tested 2-3 weeks apart. Renal function, albumin:creatinine or protein:creatinine ratio, and blood pressure should also be checked. NICE guidelines recommend urgent referral for patients aged 45 or older with unexplained visible haematuria or visible haematuria that persists or recurs after successful treatment of urinary tract infection. Patients aged 60 or older with unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test should also be urgently referred. Patients under 40 years of age with normal renal function, no proteinuria, and who are normotensive may be managed in primary care.

Intermittent Self-Catheterisation: A Safe and Effective Way to Manage Urinary Retention and Incontinence

Intermittent self-catheterisation is a safe and effective method for managing urinary retention or incontinence caused by a neuropathic or hypotonic bladder. This technique provides patients with freedom from urinary collection systems. Although it may not be feasible for some patients, severe disability is not a contra-indication. Patients in wheelchairs have successfully mastered the technique despite various physical and mental challenges.

Single-use catheters are sterile and come with either a hydrophilic or gel coating. The former requires immersion in water for 30 seconds to activate, while the latter doesn’t require any preparation before use. Reusable catheters are made of polyvinyl chloride and can be washed and reused for up to a week.

While other types of catheterisation are available, intermittent self-catheterisation is typically the first choice. Oxybutynin, an anticholinergic medication, is used to relieve urinary difficulties, including frequent urination and urge incontinence, by decreasing muscle spasms of the bladder. However, in patients with overflow incontinence due to diabetes or neurological diseases like multiple sclerosis or spinal cord trauma, oxybutynin can worsen overflow incontinence because the fundamental problem is the bladder not contracting. The same is true for imipramine.

Microscopic Haematuria and Proteinuria: Clinical Relevance and Referral

Here we have an incidental finding of microscopic haematuria and proteinuria. Microscopic haematuria is considered clinically relevant if present on at least two out of three samples tested at weekly intervals. A dipstick showing ‘trace’ blood should be considered negative, while blood 1+ or more is significant. Additionally, this patient has persistent proteinuria 1+ in all samples.

If there had been no proteinuria, a non-urgent referral to a urologist would have been the best approach given the patient’s age. However, with the presence of proteinuria, referral to a renal physician is indicated as per NICE guidance. It is important to consider these findings and take appropriate action to ensure the best possible patient outcomes.

Investigations for Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia (BPH) is a common condition in older men that can cause urinary symptoms. To diagnose BPH and rule out other potential causes, several investigations may be necessary.

Digital Rectal Examination (DRE) is the most appropriate initial investigation for BPH. It can identify an enlarged prostate and any irregular or hard areas that could indicate malignancy.

Abdominal Ultrasound (US) may be indicated after a DRE if there is evidence of raised creatinine or urinary retention, to identify evidence of reflux nephropathy.

Creatinine (Cr) is useful to investigate for acute or chronic renal impairment, which is a complication of BPH due to chronic urinary retention causing reflux nephropathy. However, it is not the most appropriate initial investigation.

Prostate-specific antigen (PSA) blood test is useful, in combination with DRE, to rule out malignancy as the cause of symptoms. However, PSA levels can be raised due to many reasons, so it is important to avoid recent ejaculation, heavy exercise, or a recent DRE before taking the test.

Urine culture is useful to rule out a urinary tract infection (UTI) as the cause of symptoms. However, it is not the most likely cause for BPH symptoms. Urine culture would be appropriate if the patient had more symptoms of a UTI, such as dysuria, fever, or abdominal pain.

Overall, a combination of investigations may be necessary to diagnose and manage BPH effectively.

Managing Anaemia in Chronic Kidney Disease Patients

Anaemia is a common occurrence in patients with severe renal impairment. The kidneys’ reduced ability to produce erythropoietin leads to normochromic, normocytic anaemia. The National Institute for Health and Care Excellence (NICE) recommends investigating and managing anaemia in patients with chronic kidney disease (CKD) if their haemoglobin level falls to 110g/l or less (105g/l if less than 2 years) or if they develop symptoms of anaemia.

Iron deficiency is a common issue in people with CKD, which may be due to poor dietary intake, occult bleeding, or functional imbalance between the iron requirements of the erythroid marrow and the actual iron supply. It is important to manage iron deficiency before starting erythropoetic stimulating agent therapy. The aspirational haemoglobin range is typically between 100 and 120g/l (95 to 115g/l if less than 2 years to reflect lower normal range in that age group).

It is not recommended to prescribe vitamin C supplements as adjuvants specifically for the anaemia of CKD. Overall, managing anaemia in CKD patients requires careful attention to iron levels and haemoglobin ranges.

Management and Prevention of Renal Stones

Renal stones, also known as kidney stones, can cause severe pain and discomfort. The British Association of Urological Surgeons (BAUS) has published guidelines on the management of acute ureteric/renal colic. Initial management includes the use of NSAIDs as the analgesia of choice for renal colic, with caution taken when prescribing certain NSAIDs due to increased risk of cardiovascular events. Alpha-adrenergic blockers are no longer routinely recommended, but may be beneficial for patients amenable to conservative management. Initial investigations include urine dipstick and culture, serum creatinine and electrolytes, FBC/CRP, and calcium/urate levels. Non-contrast CT KUB is now recommended as the first-line imaging for all patients, with ultrasound having a limited role.

Most renal stones measuring less than 5 mm in maximum diameter will pass spontaneously within 4 weeks. However, more intensive and urgent treatment is indicated in the presence of ureteric obstruction, renal developmental abnormality, and previous renal transplant. Treatment options include lithotripsy, nephrolithotomy, ureteroscopy, and open surgery. Shockwave lithotripsy involves generating a shock wave externally to the patient, while ureteroscopy involves passing a ureteroscope retrograde through the ureter and into the renal pelvis. Percutaneous nephrolithotomy involves gaining access to the renal collecting system and performing intra corporeal lithotripsy or stone fragmentation. The preferred treatment option depends on the size and complexity of the stone.

Prevention of renal stones involves lifestyle modifications such as high fluid intake, low animal protein and salt diet, and thiazide diuretics to increase distal tubular calcium resorption. Calcium stones may also be due to hypercalciuria, which can be managed with thiazide diuretics. Oxalate stones can be managed with cholestyramine and pyridoxine, while uric acid stones can be managed with allopurinol and urinary alkalinization with oral bicarbonate.

Renal/Ureteric Colic: Symptoms and Characteristics

Renal/ureteric colic is characterized by sudden and severe pain, often caused by stones. However, in some cases, no obvious cause is found. Unlike biliary or intestinal colic, the pain of renal colic is constant, with periods of relief or dull aches before it returns. The location of the pain changes as the stone moves. Patients with renal colic experience intense pain and may writhe around in agony, while those with peritoneal irritation lie still. Although there may be severe pain in the testis, it should not be tender. Uncomplicated renal colic doesn’t cause fever, which suggests pyelonephritis. Haematuria, often detected only on dipstick testing, is a common symptom.

Prostate Cancer and Prostatism: Symptoms and Diagnosis

Patients with prostatism who experience bony pain should be evaluated for prostate cancer, as it often metastasizes to bone. A digital rectal examination should be performed after taking blood for PSA, as the prostate will typically feel hard and irregular in cases of prostate cancer. While chronic urinary retention and urinary infection may be present, investigations should focus on identifying the underlying cause rather than providing symptomatic treatment with an α-blocker. Without a confirmed diagnosis of benign prostatic hyperplasia, finasteride should not be prescribed.

Prognosis of Prostate Cancer Based on Gleason Score

Prostate cancer prognosis can be predicted using the Gleason score, which is determined through histology following a hollow needle biopsy. The Gleason score is based on the glandular architecture seen on the biopsy and is calculated by adding the most prevalent and second most prevalent patterns observed. This results in a Gleason grade ranging from 1 to 5, which is then added together to obtain a Gleason score ranging from 2 to 10. The higher the Gleason score, the worse the prognosis for the patient. Therefore, the Gleason score is an important factor in determining the appropriate treatment plan for patients with prostate cancer.

The target for haemoglobin levels in CKD patients with anaemia should be between 10-12 g/dl.

Anaemia in Chronic Kidney Disease

Patients with chronic kidney disease (CKD) may develop anaemia due to various factors, with reduced erythropoietin levels being the most significant. This type of anaemia is usually normochromic normocytic and becomes apparent when the GFR is less than 35 ml/min. Other causes of anaemia should be considered if the GFR is greater than 60 ml/min. Anaemia in CKD can lead to the development of left ventricular hypertrophy, which is associated with a three-fold increase in mortality in renal patients.

There are several causes of anaemia in renal failure, including reduced erythropoietin levels, reduced erythropoiesis due to toxic effects of uraemia on bone marrow, reduced absorption of iron, anorexia/nausea due to uraemia, reduced red cell survival (especially in haemodialysis), blood loss due to capillary fragility and poor platelet function, and stress ulceration leading to chronic blood loss.

To manage anaemia in CKD, the 2011 NICE guidelines suggest a target haemoglobin of 10-12 g/dl. Determination and optimisation of iron status should be carried out before the administration of erythropoiesis-stimulating agents (ESA). Oral iron should be offered for patients who are not on ESAs or haemodialysis. If target Hb levels are not reached within three months, patients should be switched to IV iron. Patients on ESAs or haemodialysis generally require IV iron. ESAs such as erythropoietin and darbepoetin should be used in those who are likely to benefit in terms of quality of life and physical function.

Symptoms and Presentations of Various Kidney Conditions

Kidney conditions can present with a variety of symptoms and presentations. Renal colic, caused by the passage of stones into the ureter, is characterized by severe flank pain that radiates to the groin, along with haematuria, nausea, and vomiting. Acute pyelonephritis presents with fever, costovertebral angle pain, and nausea/vomiting, while acute glomerulonephritis doesn’t cause severe loin pain. Autosomal dominant polycystic kidney disease can cause chronic loin pain, but it is not as severe as renal colic unless there is a stone present. Renal cell carcinoma may present with haematuria, loin pain, and a flank mass, but the pain is not as severe as in renal colic and pyrexia is only present in a minority of cases.

Epididymo-orchitis: Causes and Treatment

Epididymo-orchitis is a condition that affects the testicles and epididymis, which are the tubes that carry sperm. It is more commonly seen in older men and can be caused by either chlamydia or gonorrhoea, or by common urinary tract organisms.

To diagnose the condition, urine testing for MSU and chlamydia or gonorrhoea can be done. However, due to the gradual onset of symptoms, empirical treatment should not be delayed. A 10-14 day course of quinolone is recommended as the first-line treatment.

For women over 65 years old with suspected urinary tract infections, it is recommended to send an MSU for urine culture according to current NICE CKS guidance. Asymptomatic bacteriuria is common in older patients, so a urine dip is no longer recommended. However, a urine culture can help determine appropriate antibiotic therapy in this age group. Antibiotics should be prescribed for 3 days in women and 7 days in men with suspected urinary tract infections. Since the woman is experiencing symptoms, it is appropriate to administer antibiotics immediately rather than waiting for culture results.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. Lower UTIs are more common and can be managed with antibiotics. For non-pregnant women, local antibiotic guidelines should be followed, and a urine culture should be sent if they are aged over 65 years or have visible or non-visible haematuria. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. Pregnant women with symptoms should have a urine culture sent, and first-line treatment is nitrofurantoin, while amoxicillin or cefalexin can be used as second-line treatment. Asymptomatic bacteriuria in pregnant women should also be treated with antibiotics. Men with UTIs should be offered antibiotics for seven days, and a urine culture should be sent before starting treatment. Catheterised patients should not be treated for asymptomatic bacteriuria, but if they are symptomatic, a seven-day course of antibiotics should be given, and the catheter should be removed or changed if it has been in place for more than seven days. For patients with signs of acute pyelonephritis, hospital admission should be considered, and local antibiotic guidelines should be followed. The BNF recommends a broad-spectrum cephalosporin or a quinolone for 10-14 days for non-pregnant women.

Varicocele: To Treat or Not to Treat?

Varicocele is a common condition found in 20% of all men in the general population and 40% of infertile men. While it may cause abnormal sperm count and infertility, controversy surrounds the need for treatment. A Cochrane review has cast doubt on the merits of varicocelectomy, but European guidelines cite several meta-analyses favoring treatment. Surgery is only indicated for persistent pain. In older men with newly symptomatic varicocele, an advanced renal tumor is possible and should be excluded. Overall, most varicoceles do not require treatment and are unlikely to cause long-term complications.

PSA Testing and Prostate Cancer Screening

Current advice from the Department of Health states that patients should not be refused a PSA test if they request one. However, patients should be informed about the implications of the test. While there is no clear evidence to support mass prostate cancer screening, studies have shown that diagnosing patients through case presentation has led to improved cancer mortality rates in the USA. It is important to note that many patients with prostate cancer do not experience symptoms, and urinary symptoms are not always indicative of the disease. Additionally, prostate cancer can develop in patients as young as their fifth decade of life.

PSA Testing for Prostate Cancer: Benefits and Limitations

PSA testing for prostate cancer in asymptomatic men is a contentious issue with some advocating it as a screening test and others wary of over-treatment and patient harm. It is important to clearly impart the benefits and limitations of PSA testing to the patient so that they can make an informed decision about whether to be tested.

One of the main debates surrounding PSA testing is its limitations in terms of sensitivity and specificity. Two out of three men with a raised PSA will not have prostate cancer, and 15 out of 100 with a negative PSA will have prostate cancer. Additionally, PSA testing cannot distinguish between slow and fast-growing cancers, leading to potential over-treatment.

There is also debate about the frequency of PSA testing. Patients with elevated PSA levels who are undergoing surveillance often have PSA levels done every three to six months, but how often should a PSA level be repeated in an asymptomatic man who has had a normal result? Some experts suggest a normal PSA in an asymptomatic man doesn’t need to be repeated for at least two years.

When it comes to prostate cancer treatment, approximately 48 men need to undergo treatment in order to save one life. It is important for patients to weigh the potential benefits and limitations of PSA testing before making a decision.

Balanitis: Causes and Management

Balanitis is a common condition that presents in general practice. It can have various causes, but the most likely cause in many cases is an irritant reaction from excessive washing and use of soaps. Other common causes include Candida, psoriasis, and other skin conditions. If there is any discharge, swabbing should be done. If ulceration is present, herpes simplex virus (HSV) should be considered. In older men with persistent symptoms, Premalignant conditions and possible biopsy may be considered.

The management of balanitis involves advice, reassurance, and a topical steroid as the initial treatment. Testing for glycosuria should be considered to rule out Candida. If the symptoms persist, further investigation may be necessary to determine the underlying cause. It is important to identify the cause of balanitis to ensure appropriate management and prevent recurrence. By understanding the causes and management of balanitis, healthcare professionals can provide effective care to patients with this condition.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. Lower UTIs are more common and can be managed with antibiotics. For non-pregnant women, local antibiotic guidelines should be followed, and a urine culture should be sent if they are aged over 65 years or have visible or non-visible haematuria. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. Pregnant women with symptoms should have a urine culture sent, and first-line treatment is nitrofurantoin, while amoxicillin or cefalexin can be used as second-line treatment. Asymptomatic bacteriuria in pregnant women should also be treated with antibiotics. Men with UTIs should be offered antibiotics for seven days, and a urine culture should be sent before starting treatment. Catheterised patients should not be treated for asymptomatic bacteria, but if they are symptomatic, a seven-day course of antibiotics should be given, and the catheter should be removed or changed if it has been in place for more than seven days. For patients with signs of acute pyelonephritis, hospital admission should be considered, and local antibiotic guidelines should be followed. The BNF recommends a broad-spectrum cephalosporin or a quinolone for 10-14 days for non-pregnant women.

Common Causes of Urinary Tract Obstruction in Children

Urinary tract obstruction in children can lead to a poor urinary stream, indicating a blockage in the urinary system. The most common cause of this condition in boys is posterior urethral valves (PUVs), which are folds of urothelium that obstruct the bladder. PUVs can range in severity, from life-threatening to asymptomatic, but can lead to end-stage renal disease in 30% of patients. Vesicoureteric reflux, the backward flow of urine from the bladder into the kidneys, is also common in PUV patients.

Antenatal ultrasound has increased the diagnosis of PUVs, with most cases recognized during the second and third trimester. Delayed presentation can include urinary infection, enuresis, voiding pain or dysfunction, and an abnormal urinary stream. Neurogenic bladder, caused by a birth defect involving the spinal cord, can also lead to urinary retention, leakage, and infection. Urethral calculi and strictures are less common causes of urinary tract obstruction in children, but should still be considered in the differential diagnosis.

Referral Guidelines for Recurrent UTI with Non-Visible Haematuria

Recurrent UTI is defined as three or more episodes in a year. In the case of a woman with her fourth episode in the last six months, it is important to investigate further. If visible or non-visible haematuria is present on dipstick testing when a UTI is suspected, a urine sample should be sent to the laboratory for mc+s testing in all patients. If infection is confirmed, a urine sample should be dipstick tested for blood after antibiotic treatment has been completed. If haematuria persists, further investigation is warranted.

According to NICE guidelines, urgent referral is necessary for bladder cancer if a person aged 45 and over has unexplained visible haematuria without urinary tract infection or visible haematuria that persists or recurs after successful treatment of urinary tract infection. For renal cancer, urgent referral is necessary if a person aged 45 and over has unexplained visible haematuria without urinary tract infection or visible haematuria that persists or recurs after successful treatment of urinary tract infection.

In the case of a woman with recurrent UTIs associated with non-visible haematuria each time, urgent referral to a urologist is necessary. It is important to follow these guidelines to ensure timely diagnosis and treatment of potential cancer.

Urgent Referral for Painless Visible Haematuria

Painless macroscopic haematuria, or visible blood in the urine, is a concerning symptom that should be urgently referred for suspicion of bladder or renal cancer. However, it is important to note that if the patient also experiences pain or symptoms of a urinary tract infection, these should be assessed and managed separately.

Prompt referral for painless visible haematuria is crucial in order to ensure timely diagnosis and treatment of potential cancer. Patients should be advised to seek medical attention immediately if they notice blood in their urine, even if they do not experience any pain or other symptoms. Healthcare providers should also be vigilant in identifying and referring these cases for further evaluation.

Considerations for Ring Pessary Use in Patients with Specific Conditions

Ring pessaries are a non-surgical option for managing pelvic organ prolapse. However, certain patient factors must be considered before recommending this treatment.

Inability to attend follow-up care is a significant concern for patients using ring pessaries. These devices need to be changed every six months, and patients with poor mobility may require assistance from a healthcare provider. Failure to change the pessary can lead to infection and other complications. Therefore, patients who cannot attend follow-up appointments may not be suitable candidates for ring pessary use.

Obesity is a risk factor for pelvic organ prolapse, but it is not a contraindication for ring pessary use. In fact, weight loss may help alleviate the condition along with pessary use.

Age is not a barrier to pessary insertion. In fact, ring pessaries are often used in older or frailer patients where surgery is less desirable.

Sexual activity is not a contraindication for ring pessary use. Patients can leave the pessary in during intercourse, but some may find it uncomfortable. In such cases, the ring can be removed and reinserted after intercourse, or an alternative type of pessary can be tried.

Mild cognitive impairment doesn’t preclude pessary use, but patients may require additional follow-up to ensure the device is removed and replaced every six months.

Understanding Renal Function: Estimating Glomerular Filtration Rate

Renal function is a crucial aspect of overall health, and it is typically measured by estimating the glomerular filtration rate (GFR). There are various equations available to calculate GFR, but the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation is recommended by NICE. This equation takes into account serum creatinine, age, gender, and race.

It is important to note that laboratories often assume a standard body surface area, which can lead to inaccurate results in individuals with extreme muscle mass. For example, bodybuilders, amputees, and those with muscle wasting disorders may have an overestimated or underestimated GFR.

Additionally, certain factors can affect serum creatinine levels and thus impact the accuracy of eGFR results. For instance, consuming a cooked meat meal can temporarily increase serum creatinine concentration, leading to a falsely lowered eGFR. Conversely, strict and long-term vegetarians may have a reduced baseline eGFR.

If an eGFR result is less than 60 ml/min/1.73m2 in someone who has not been previously tested, it is recommended to confirm the result by repeating the test in two weeks.

Finally, it is worth noting that creatinine clearance is sometimes used as a rough measurement of GFR, but it has limitations. This method involves a 24-hour urine collection and a serum creatinine measurement during that time period. However, accurate urine collection can be challenging, and this method tends to overestimate GFR and is time-consuming.

Overall, understanding how to estimate GFR and interpret the results is crucial for assessing renal function and identifying potential health concerns.

This man is likely to have stage 3 chronic kidney disease (CKD). If an initial abnormal eGFR result is detected, it is important to conduct clinical assessment and repeat the test within 2 weeks to evaluate the rate of change in GFR. If CKD is confirmed, at least three eGFR assessments should be made over a period of not less than 90 days to monitor the rate of change in GFR. The frequency of eGFR monitoring will depend on the severity of kidney impairment. Significant progression of CKD is defined as a decline in eGFR of > 5 ml/min/1.73 m² within 1 year or >10 ml/min/1.73 m² within 5 years.

Proteinuria should be assessed by measuring the protein:creatinine or albumin:creatinine ratio, ideally on an early-morning urine specimen. Proteinuria (ACR ≥30 mg/mmol) together with haematuria may indicate glomerulonephritis and is an indication for referral. However, dipstick testing for haematuria is a screening tool that requires microscopy to make a definitive diagnosis. Haematuria is defined as >3 RBC/high power field of centrifuged sediment under the microscope. If there is only a trace, a sample needs to be sent to confirm haematuria. Patients with CKD should have their proteinuria level assessed at least annually.

To manage CKD, systolic blood pressure should be lowered to <140 mm Hg (target range 120-139 mmHg) and diastolic blood pressure to <90 mm Hg. Atorvastatin 20 mg should be offered for the primary or secondary prevention of CVD to people with CKD.

The updated guidelines from the British Society for Rheumatology recommend that urate-lowering therapy should be initiated early after the first episode of gout. Therefore, it is suggested that all patients should be offered this therapy after their initial attack, rather than waiting for further episodes or ongoing symptoms. It is important to note that colchicine cannot be used as a long-term urate-lowering medication on its own. There is no need to wait for a month before starting allopurinol, as long as the acute attack has resolved. Although allopurinol can still be prescribed for patients with renal impairment, caution must be taken with the dosage. Febuxostat should only be considered as a second line medication if allopurinol is not suitable or has not been tolerated by the patient.

Gout is caused by chronic hyperuricaemia and is managed acutely with NSAIDs or colchicine. Urate-lowering therapy (ULT) is recommended for patients with >= 2 attacks in 12 months, tophi, renal disease, uric acid renal stones, or prophylaxis if on cytotoxics or diuretics. Allopurinol is first-line ULT, with a delayed start recommended until inflammation has settled. Lifestyle modifications include reducing alcohol intake, losing weight if obese, and avoiding high-purine foods. Other options for refractory cases include febuxostat, uricase, and pegloticase.

Patients who have recently started treatment are commonly affected by neuroleptic malignant syndrome, which can lead to renal failure due to rhabdomyolysis.

Neuroleptic malignant syndrome is a rare but serious condition that can occur in patients taking antipsychotic medication or dopaminergic drugs for Parkinson’s disease. It can also occur with atypical antipsychotics. The exact cause of this condition is unknown, but it is believed that dopamine blockade induced by antipsychotics triggers massive glutamate release, leading to neurotoxicity and muscle damage. Symptoms typically appear within hours to days of starting an antipsychotic and include fever, muscle rigidity, autonomic lability, and agitated delirium with confusion. A raised creatine kinase is present in most cases, and acute kidney injury may develop in severe cases.

Management of neuroleptic malignant syndrome involves stopping the antipsychotic medication and transferring the patient to a medical ward or intensive care unit. IV fluids are given to prevent renal failure, and dantrolene may be useful in selected cases. Dantrolene works by decreasing excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor and decreasing the release of calcium from the sarcoplasmic reticulum. Bromocriptine, a dopamine agonist, may also be used. It is important to note that neuroleptic malignant syndrome is different from serotonin syndrome, although both conditions can cause a raised creatine kinase.

During pregnancy, GFR typically experiences an increase, although this may not be reflected in the eGFR.

Chronic kidney disease (CKD) is a condition where the kidneys are not functioning properly. To estimate renal function, serum creatinine levels are often used, but this may not be accurate due to differences in muscle. Therefore, formulas such as the Modification of Diet in Renal Disease (MDRD) equation are used to estimate the glomerular filtration rate (eGFR). The MDRD equation takes into account serum creatinine, age, gender, and ethnicity. However, factors such as pregnancy, muscle mass, and recent red meat consumption may affect the accuracy of the result.

CKD can be classified based on the eGFR. Stage 1 CKD is when the eGFR is greater than 90 ml/min, but there are signs of kidney damage on other tests. If all kidney tests are normal, there is no CKD. Stage 2 CKD is when the eGFR is between 60-90 ml/min with some sign of kidney damage. Stage 3a and 3b CKD are when the eGFR is between 45-59 ml/min and 30-44 ml/min, respectively, indicating a moderate reduction in kidney function. Stage 4 CKD is when the eGFR is between 15-29 ml/min, indicating a severe reduction in kidney function. Stage 5 CKD is when the eGFR is less than 15 ml/min, indicating established kidney failure, and dialysis or a kidney transplant may be necessary. It is important to note that normal U&Es and no proteinuria are required for a diagnosis of CKD.